Loading...
Microfluidic affinity selection of active SARS-CoV-2 virus particles
Gamage, Sachindra S. T. Pahattuge, Thilanga N. Wijerathne, Harshani Childers, Katie Vaidyanathan, Swarnagowri Athapattu, Uditha S. Zhang, Lulu Zhao, Zheng Hupert, Mateusz L. Muller, Rolf M.
Gamage, Sachindra S. T.
Pahattuge, Thilanga N.
Wijerathne, Harshani
Childers, Katie
Vaidyanathan, Swarnagowri
Athapattu, Uditha S.
Zhang, Lulu
Zhao, Zheng
Hupert, Mateusz L.
Muller, Rolf M.
Citations
Altmetric:
Abstract
We report a microfluidic assay to select active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral particles (VPs), which were defined as intact particles with an accessible angiotensin-converting enzyme 2 receptor binding domain (RBD) on the spike (S) protein, from clinical samples. Affinity selection of SARS-CoV-2 particles was carried out using injection molded microfluidic chips, which allow for high-scale production to accommodate large-scale screening. The microfluidic contained a surface-bound aptamer directed against the virus’s S protein RBD to affinity select SARS-CoV-2 VPs. Following selection (~94% recovery), the VPs were released from the chip’s surface using a blue light light-emitting diode (89% efficiency). Selected SARS-CoV-2 VP enumeration was carried out using reverse transcription quantitative polymerase chain reaction. The VP selection assay successfully identified healthy donors (clinical specificity = 100%) and 19 of 20 patients with coronavirus disease 2019 (COVID-19) (95% sensitivity). In 15 patients with COVID-19, the presence of active SARS-CoV-2 VPs was found. The chip can be reprogrammed for any VP or exosomes by simply changing the affinity agent.
Description
Date
2022-09-28
Journal Title
Journal ISSN
Volume Title
Publisher
American Association for the Advancement of Science
Collections
Files
Loading...
Gamage_2022.pdf
Adobe PDF, 2.69 MB
Research Projects
Organizational Units
Journal Issue
Keywords
Citation
Gamage, Sachindra S T et al. “Microfluidic affinity selection of active SARS-CoV-2 virus particles.” Science advances vol. 8,39 (2022): eabn9665. doi:10.1126/sciadv.abn9665